Ard-101: H.E.R.O

In this webinar, we are joined by Aardvark Therapeutics, who share details about upcoming UK trial sites for ARD-101, a novel, orally administered investigational therapy. ARD-101 is currently being studied for its potential to reduce excessive hunger and food-seeking behaviours in individuals with Prader-Willi syndrome (PWS).

We are also joined by Dr Evelien Gevers, Consultant Paediatrician in Endocrinology and Diabetes at Barts NHS Trust in London, and Dr Guftar Shaikh, Consultant Paediatric Endocrinologist at Glasgow’s Royal Hospital for Children, who explain the trial process and outline what participants can expect.

Further Updates

Watch our third webinar, where we are joined by Consynance, who provide an update on their Phase 2 CSTI500 trial. Soleno discusses their burden of disease survey supporting the DCCR trial, while Dr. Evelien Gevers explains what to expect when attending a trial screening. Lastly, Helen from FPWR UK shares updates on current trials in the UK.

Clinical Trial Updates

Watch our second webinar where we are joined by Harmony Biosciences, Aardvark, Soleno and Arcadia who update us on their clinical trials. 

What Are Clinical Trials?

Watch our first webinar, we covered everything you need to know about clinical trials.